Robert W. Baird Lowers Certara (NASDAQ:CERT) Price Target to $13.00

Certara (NASDAQ:CERT - Get Free Report) had its target price cut by stock analysts at Robert W. Baird from $18.00 to $13.00 in a note issued to investors on Tuesday, Benzinga reports. The firm currently has a "neutral" rating on the stock. Robert W. Baird's price target would suggest a potential upside of 26.09% from the company's previous close.

Other analysts have also issued reports about the stock. Barclays lowered their target price on shares of Certara from $16.00 to $14.00 and set an "equal weight" rating for the company in a research note on Tuesday, October 15th. JMP Securities reissued a "market perform" rating on shares of Certara in a research note on Wednesday, July 10th. KeyCorp lowered their target price on Certara from $23.00 to $20.00 and set an "overweight" rating for the company in a report on Thursday, July 11th. Finally, UBS Group upgraded Certara from a "neutral" rating to a "buy" rating and set a $16.00 price target on the stock in a research note on Friday, September 27th. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, Certara has an average rating of "Hold" and a consensus price target of $16.25.

Certara Trading Up 0.6 %

NASDAQ CERT traded up $0.06 on Tuesday, hitting $10.31. 1,023,583 shares of the stock were exchanged, compared to its average volume of 777,852. Certara has a 52-week low of $9.99 and a 52-week high of $19.87. The firm has a market capitalization of $1.66 billion, a P/E ratio of -20.62, a P/E/G ratio of 4.88 and a beta of 1.51. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.61 and a current ratio of 2.61. The stock has a fifty day moving average price of $11.16 and a two-hundred day moving average price of $13.81.

Certara (NASDAQ:CERT - Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. The business had revenue of $93.31 million for the quarter, compared to analysts' expectations of $96.01 million. During the same quarter last year, the firm earned $0.10 EPS. The firm's quarterly revenue was up 3.2% on a year-over-year basis. Research analysts forecast that Certara will post 0.27 EPS for the current fiscal year.

Insider Activity

In related news, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the sale, the insider now owns 50,091 shares of the company's stock, valued at $552,503.73. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Certara news, insider Patrick F. Smith sold 5,409 shares of the firm's stock in a transaction on Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the transaction, the insider now owns 50,091 shares of the company's stock, valued at approximately $552,503.73. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Leif E. Pedersen sold 51,224 shares of the business's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.29, for a total value of $578,318.96. Following the sale, the insider now owns 99,704 shares in the company, valued at approximately $1,125,658.16. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.39% of the company's stock.

Institutional Trading of Certara

Several hedge funds and other institutional investors have recently bought and sold shares of CERT. Versor Investments LP purchased a new stake in Certara in the 3rd quarter worth approximately $162,000. TimesSquare Capital Management LLC grew its position in Certara by 3.1% during the third quarter. TimesSquare Capital Management LLC now owns 956,655 shares of the company's stock valued at $11,202,000 after buying an additional 29,090 shares during the period. Atria Investments Inc raised its position in shares of Certara by 21.6% in the third quarter. Atria Investments Inc now owns 19,743 shares of the company's stock worth $231,000 after acquiring an additional 3,501 shares during the period. Harbor Capital Advisors Inc. boosted its stake in shares of Certara by 18.4% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 20,144 shares of the company's stock worth $236,000 after acquiring an additional 3,136 shares in the last quarter. Finally, Everence Capital Management Inc. grew its position in shares of Certara by 21.0% during the 3rd quarter. Everence Capital Management Inc. now owns 14,910 shares of the company's stock valued at $175,000 after acquiring an additional 2,590 shares during the period. 73.96% of the stock is owned by institutional investors and hedge funds.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.